Physician
Hematology
Dr. Alan Saven, MD
|
|
Give Review
Alan Saven works in the field of Hematology. He over the years received 6 awards: "America's Top Doctors", "Top Doctors:San Diego Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California", "Super Doctor" and "Top MD". Alan Saven has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia.' He is registered with Medicare and accepts Medicare payments.
Publications
- Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review.
- Hairy cell Leukemia: a 'hair-raising' update.
- Clinical Characteristics and Long-Term Outcome of Young Hairy Cell Leukemia Patients Treated With Cladribine: A Single Institution Series.
- Masquerade without a mass: an unusual cause of severe Acute pancreatitis.
- Cladribine activity in systemic mast Cell disease: application of biochemistry in the modern era of molecular biology.
- Cladribine: from the bench to the bedside--focus on hairy cell Leukemia.
- Combinatorial antibody libraries from Cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast Cancer metastasis.
- SHP1 expression in bone marrow biopsies of myelodysplastic Syndrome patients: a new prognostic factor.
- Reactive thrombocytosis associated with a pheochromocytoma.
- Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
- Cladribine in hairy cell Leukemia.
- Use of optophoresis as an in vitro predictor of cell response to chemotherapy for chronic lymphocytic Leukemia.
- Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
- How valid is using Cancer registries'' data to identify acquired immunodeficiency syndrome-related non-Hodgkin''s lymphoma?
- Understanding hairy cell Leukemia genetics.
- Hairy cell Leukemia.
- Cladribine in indolent non-Hodgkin''s Lymphoma.
- KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
- Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia.
- Cladribine in the treatment of hairy cell Leukemia: initial and subsequent results.
- Very long-term eradication of minimal residual disease in patients with hairy cell Leukemia after a single course of cladribine.
- In vivo targeting of B-Cell lymphoma with glycan ligands of CD22.
- Beyond hairy Cell: the activity of cladribine in other hematologic malignancies.
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: R...
- Hairy cell Leukemia: current therapies and future directions.
- Development of cladribine at Scripps for hairy cell Leukemia and current results.
- Primary intraocular Lymphoma: a review.
- Targeting B Lymphoma with nanoparticles bearing glycan ligands of CD22.
- My treatment approach to hairy cell Leukemia.
- 2-Chlorodeoxyadenosine treatment of low-grade Lymphomas.
- 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-Cell lymphoma.
- Treatment of hairy cell Leukemia.
- Gaucher Disease. Clinical, laboratory, radiologic, and genetic features of 53 patients.
- Hodgkin's Disease.
- 2-Chlorodeoxyadenosine chemotherapy triggers programmed Cell death in normal and malignant lymphocytes.
- Enzyme replacement therapy in type I Gaucher Disease.
- Enzyme replacement therapy for Gaucher Disease.
- Misuse of marrow examination in the diagnosis of Gaucher Disease.
- Dilutional acidosis.
- Iron overload after prolonged intramuscular iron therapy.
- Indomethacin and the nephrotic Syndrome.
- Aminophylline allergy.
- Morbidity trends in the medical wards at Groote Schuur Hospital--1971 and 1982.
- The optimal management of hairy Cell leukaemia.
- 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's Lymphoma.
- Hairy cell Leukemia: new understanding of biology and treatment.
- Diagnostic application of two-color flow cytometry in 161 cases of hairy cell Leukemia.
- The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell Leukemia.
- 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic Leukemia.
- The newer purine Analogs. Significant therapeutic advance in the management of lymphoid malignancies.
- Newer purine analogues for the treatment of hairy-cell Leukemia.
- 2-Chlorodeoxyadenosine in the treatment of hairy cell Leukemia and chronic lymphocytic Leukemia.
- 2-Chlorodeoxyadenosine: a newer purine Analog active in the treatment of indolent lymphoid malignancies.
- Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
- 2-Chlorodeoxyadenosine therapy in chronic lymphocytic Leukemia.
- Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous Leukemia after 2-chlorodeoxyadenosine.
- 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-Cell histiocytosis.
- Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell Leukemia and chronic lymphocytic Leukemia.
- Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell Leukemia.
- Purine metabolism of lymphocytes. Targets for chemotherapy drug development.
- Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.
- 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic Leukemia resistant to fludarabine.
- 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
- 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.
- Complete remissions in hairy cell Leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
- 2-Chlorodeoxyadenosine to treat refractory histiocytosis X.
- 2-Chlorodeoxyadenosine in the treatment of hairy cell Leukemia.
- Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic Leukemia as a model.
- Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.
- Acute myelogenous leukemia presenting with bulky lymphadenopathy. Case report and literature review.
- Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's Lymphoma.
- Fludarabine treatment and transfusion-associated graft-versus-host Disease.
- The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic Leukemia.
- New perspectives on the approach to chronic lymphocytic Leukemia.
- Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia.
- Outpatient high-dose chemotherapy with autologous stem-Cell rescue for hematologic and nonhematologic malignancies.
- Major activity of cladribine in patients with de novo B-cell prolymphocytic Leukemia.
- 2-Chlorodeoxyadenosine treatment of Lymphoma.
- 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative Disorders.
- 2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous Leukemia.
- Peripheral T-Cell lymphoma after anti-CD20 antibody therapy.
- Splenectomy for hairy cell Leukemia in pregnancy.
- Long-term follow-up of patients with hairy cell Leukemia after cladribine treatment.
- Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia.
- Mastocytosis: diverse presentations and outcomes.
- Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell Leukemia.
- Cladribine activity in adult langerhans-Cell histiocytosis.
- Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin''s Lymphoma.
- Treatment of hairy cell Leukemia-variant with cladribine.
- Delayed onset of autoimmune hemolytic Anemia complicating cladribine therapy for Waldenström macroglobulinemia.
- An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis.
- Integrin activation controls metastasis in human breast Cancer.
- Therapeutic advances in the treatment of hairy cell Leukemia.
- A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
- Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with Cancer.
- Treatment of hairy-cell Leukemia.
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous Leukemia in myeloid blast crisis: results of a phase II study.
- A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic Leukemia: results from CALGB Study 9211.
- Extended follow-up of patients with hairy cell Leukemia after treatment with cladribine.
- Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell Leukemia.
Schools
University Of Cape Town Faculty Of Health Sciences
Groote Schuur Hospital
Albert Einstein Med Center
Scripps Clin
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:San Diego Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Super Doctor
- Top MD
Education
-
Scripps Clinic -
Albert Einstein Healthcare Network -
University of Cape Town Faculty of Medicine
Drug Facts
| NPI NUMBER | 1184680399 | |
| NPPES Provider LastName | SAVEN | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 920371027 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 747.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184680399 |
| Last Name Of The Provider | SAVEN |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
|
Dr. Joel I. Bernstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter T. Curtin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marie P. Shieh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua D. Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ewa K. Carrier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard B. Schwab, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caitlin L. Costello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James N. Ho, MD |
|
|
Dr. Rahul R. Naik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Randall Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Imawati B. Wong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francisco M. Wong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina A. To, MD |
|
|
Dr. Edna I. Flores, MD
This Doctor is OpenDoctor Recommended.
|